Trends in targeted delivery of nanomaterials in colon cancer diagnosis and treatment
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Colon cancer is an adenocarcinoma, which subsequently develops into malignant tumors, if not treated properly. The current colon cancer therapy mainly revolves around chemotherapy, radiotherapy and surgery, but the search continues for more effective interventions. With the advancement of nanoparticles (NPs), it is now possible to diagnose and treat colon cancers with different types, shapes, and sizes of NPs. Nanoformulations such as quantum dots, iron oxide, polymeric NPs, dendrimers, polypeptides, gold NPs, silver NPs, platinum NPs, and cerium oxide have been either extensively used alone or in combination with other nanomaterials or drugs in colon cancer diagnosis, and treatments. These nanoformulations possess high biocompatibility and bioavailability, which makes them the most suitable candidates for cancer treatment. The size and shape of NPs are critical to achieving an effective drug delivery in cancer treatment and diagnosis. Most NPs currently are under different testing phases (in vitro, preclinical, and clinical), whereas some of them have been approved for therapeutic applications. We have comprehensively reviewed the recent advances in the applications of NPs‐based formulations in colon cancer diagnosis and treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Bright quantum dots emitting at ∼1,600 nm in the NIR-IIb window for deep tissue fluorescence imaging
Zhang, M., Yue, J., Cui, R., Ma, Z., Wan, H., Wang, F., Zhu, S., Zhou, Y., Kuang, Y., Zhong, Y., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1806153115 · Cited by 432
An intestinal Trojan horse for gene delivery
Peng, H., Wang, C., Xu, X., Yu, C., & Wang, Q. (2015) · Nanoscale · doi:10.1039/c4nr06377e · Cited by 66
Cited by
Current Status and Emerging Trends in Colorectal Cancer Screening and Diagnostics
Beniwal, S., Lamo, P., Kaushik, A., Lorenzo-Villegas, D., Liu, Y., & MohanaSundaram, A. (2023) · Biosensors · doi:10.3390/bios13100926 · Cited by 60
“This is attributed to the unique physicochemical properties inherent in nanomaterials, which enable efficient biomarker capture and amplification due to their substantial surface area-to-volume ratio [54,55].”
BackgroundYue, N.-N., Xu, H.-M., Xu, J., Zhu, M.-Z., Zhang, Y., Tian, C.-M., Nie, Y.-Q., Yao, J., Liang, Y.-J., Li, D.-F., et al. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s413141 · Cited by 46
An updated landscape on nanopharmaceutical delivery for mitigation of colon cancer
Shahzad, M., Hameed, H., Amjad, A., Khan, M. A., Qureshi, I. S., Hameed, A., Saeed, A., & Munir, R. (2025) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-024-03482-0 · Cited by 7
Metadata
- Authors
- Khan, F. A., Albalawi, R., & Pottoo, F. H.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2021-04-23
- Volume
- 42
- Issue
- 1
- Pages
- 227-258
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W3155438336
- Cited by
- 95
- References
- 3
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.